[HTML][HTML] Semaglutide and cardiovascular outcomes in obesity without diabetes
AM Lincoff, K Brown-Frandsen… - … England Journal of …, 2023 - Mass Medical Soc
Background Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether
semaglutide can reduce cardiovascular risk associated with overweight and obesity in the
absence of diabetes is unknown. Methods In a multicenter, double-blind, randomized,
placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or
older who had preexisting cardiovascular disease and a body-mass index (the weight in …
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether
semaglutide can reduce cardiovascular risk associated with overweight and obesity in the
absence of diabetes is unknown. Methods In a multicenter, double-blind, randomized,
placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or
older who had preexisting cardiovascular disease and a body-mass index (the weight in …
Semaglutide and cardiovascular outcomes in obesity without diabetes
D Yavuz - 2023 - openaccess.marmara.edu.tr
Background: Semaglutide, a glucagon-like peptide-1 receptor agonist, has been shown to
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether
semaglutide can reduce cardiovascular risk associated with overweight and obesity in the
absence of diabetes is unknown. Methods: In a multicenter, double-blind, randomized,
placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or
older who had preexisting cardiovascular disease and a body-mass index (the weight in …
reduce the risk of adverse cardiovascular events in patients with diabetes. Whether
semaglutide can reduce cardiovascular risk associated with overweight and obesity in the
absence of diabetes is unknown. Methods: In a multicenter, double-blind, randomized,
placebo-controlled, event-driven superiority trial, we enrolled patients 45 years of age or
older who had preexisting cardiovascular disease and a body-mass index (the weight in …